Last reviewed · How we verify

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus — Treatment Landscape & Competitive Intelligence

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Prandin repaglinide Novo Nordisk Glinide [EPC] ATP-binding cassette sub-family C member 8 1997-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Novo Nordisk · 1 drug in Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus:

Cite this brief

Drug Landscape (2026). Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adjunct-to-diet-and-exercise-to-improve-glycemic-control-in-adults-with-type-2-diabetes-mellitus. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing